Table 3.

Transplantation of pig livers into NHPs (1998–2013)

FIRST AUTHOR (Year)	DONOR (pig)	RECIPIENT (n)	IMMUNOSUPRESSIVE THERAPY	SURVIVAL – RANGE (MEDIAN) (Hours)
Luo (1998)	WT	Baboons (n=2) Rhesus (n=6)	CyP, CsA, CS None (n=3) Cyp, CsA, CS, Dashen (traditional Chinese medicine) (n=3)	<2 <6
Ramirez (2000)	WT CD55	Baboon (n=3) Baboon (n=2)	CyP, CsA, CS	<12 96,192
Ramirez (2005)	WT CD46/CD59/FT	Baboon (n=4) Baboon (n=5)	Anti-CD25mAb, CyP, anti-CD20mAb, CsA, MMF, CS	<16 13–24 (20)
Ekser (2010)	WT GTKO GTKO/CD46	Baboon (n=1) Baboon (n=2) Baboon (n=8)	ATG, CyP, CVF, tacrolimus, MMF, CS	<24 <24,144 <24–168 (144)
Kim (2012)	GTKO	Baboon (n=3)	ATG, LoCd2b, CVF, anti-CD154mAb, azathioprine, tacrolimus, CS	72–216

Abbreviations as used previously

Table 3: References

Ekser B, Long C, Echeverri GJ et al. Impact of thrombocytopenia on survival of baboons with genetically modified pig liver transplants: clinical relevance. Am J Transplant 2010; 10:273–285.

Kim K, Scheutz C, Elias N, et al. Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons. Xenotransplantation 2012; 19:256–264.

Ramirez P, Chavez R, Majado M et al. Life-supportinghuman complement regulator decay accelerating factor transgenic pig liver xenograft maintains the metabolic function and coagulation in the nonhuman primate for upto 8 days. Transplantation 2000; 70:989–998.

Ramírez P, Montoya MJ, Ríos A, García Palenciano C, Majado M, Chávez R, et al. Prevention of hyperacute rejection in a model of orthotopic liver xenotransplantation from pig to baboon using polytransgenic pig livers (CD55, CD59, and H-transferase). Transplant Proc 2005; 37:4103–6.